Keita Mori, MBA,
SanBio Co., Ltd. President
SanBio, Inc. Chairman
Mr. Mori has been Co-Chief Executive Officer and has served as a member of the Board since SanBio's inception in 2001. Prior to founding SanBio, Mr. Mori was Head of New Product Development from 2000 to 2001 at Xuma, an informatics startup in San Francisco. From 1993 to 1999, Mr. Mori held positions of increasing responsibility in R&D and Manufacturing at Kirin Holdings, Ltd. in Japan. Mr. Mori holds an MBA degree from the University of California, Berkeley and a master's degree in Biochemistry from the University of Tokyo.
SanBio Co., Ltd. Exective Chairman
Mr. Kawanishi served as SanBio's Chairman of the Board from 2001 to 2005 and has been Co-Chief Executive Officer and a member of the Board since 2005. Prior to founding SanBio, Mr. Kawanishi co-founded CareNet, Inc. (TSE: 2150) and was Executive Vice President from 1996 to 1999. At CareNet, Mr. Kawanishi established eHealthcare in Japan. From 1993 to 1996, Mr. Kawanishi was a management consultant at the Boston Consulting Group. Mr. Kawanishi has a master's degree in Biochemistry from the University of Tokyo.
Akihiro Tsujimura, MBA,
SanBio Co., Ltd. Senior Corporate Officer
SanBio, Inc. CEO
Mr. Tsujimura amassed wide-ranging experience regarding overseas business administration with Nichimen Corporation (now Sojitz Corporation) and also collected a wealth of pharmaceutical business experience working with Santen Pharmaceutical Co., Ltd., where he concluded sales license agreements, conducted M&A, and managed overseas expansion. Mr. Tsujimura is a former member of the Board at Santen Pharmaceutical Co., Ltd. and served as CEO of Santen Inc. He graduated from Kanazawa University with a B.S. in Chemical Industry. Mr. Tsujimura holds an MBA from Kobe University.
Bijan Nejadnik, M.D.,
Corporate Officer, Chief Medical Officer and Head of Research
Dr. Nejadnik has more than two decades of productive experience in large pharma and small biotech companies, as well as in academic institutions, leading research teams and organizations in developing and marketing biologics, small molecules and genetically modified cell therapy. He led the programs from early phase to registration trials, with successful BLA/NDA/MAA submissions and market launch. He was teaching faculty at University of California and Stanford University. He held multiple key roles at Johnson & Johnson working on numerous compounds in early and late stage registrational trials in Alzheimer diseases immunology, autoimmune disorders, hematology and oncology. After more than seven years of highly successful work, he joined Jazz Pharmaceuticals as Executive Director, where he led the clinical team towards an approved biologic license application (BLA) and was the lead of medical affairs division, for the launch of the FDA approved drugs. Dr. Nejadnik was –Chief Medical Officer, at Galena Biopharma and later at Eureka Therapeutics, where he was responsible for all clinical development programs, regulatory, cell manufacturing and medical affairs. Dr. Nejadnik graduated from the University of Louvain in Belgium for both his undergraduate degree in premedical studies, graduating Summa Cum Laude, and his medical degree (M.D.), graduating Magna Cum Laude. He completed his post graduate fellowships at Cornell University and Johns Hopkins University.
Takehiko Kaneko, M.D.,
Medical Director and Head of Development Japan
Taking advantage of his career as a medical doctor, Dr. Kaneko has garnered extensive experience in clinical development of pharmaceuticals. Prior to joining SanBio, he served as a member of Oncology Medical Affairs at Bristol-Myers Squibb Company. Dr. Kaneko was also engaged in clinical development at both Pfizer Inc. (US) and Pfizer Japan Inc., at the latter as a Japan Clinical Lead in charge of pharmaceutical development in the areas of neurology and urology. He took part in early development at Novartis Pharma K.K., and managed various development projects spanning autoimmune, blood, neurological, and renal disorders. Dr. Kaneko received his medical degree from Keio University School of Medicine.
Mohammad El-Kalay, Ph.D.,
Senior Vice President, Technical Operations
Dr. El-Kalay has one of the industry’s most extensive backgrounds in the development and manufacturing of cell therapies. He served as a key team member in pioneering companies such as Applied Immune Sciences, Systemix, and Osiris Therapeutics, then led technical operations teams in Vice President roles at Morphogen Pharmaceuticals, Telos Pharmaceuticals, and MicroIslet. Dr. El-Kalay founded a cellular therapy company EyeCyte, focusing on retinal diseases, and served as its Chief Executive Officer until 2013. Recently he served as Vice President of Process Development and Manufacturing at StemCells, Inc. and as Vice President of Technical Operations at Sangamo Therapeutics.
Dr. El-Kalay holds a Ph.D. in Chemical/Biomedical from Strathclyde University, Glasgow.
Haruhiko Tsumura, Ph.D.,
Head of Production
Dr. Tsumura has extensive experience in production, development, and education of biopharmaceuticals. Prior to joining SanBio, he served as Head of Production Planning and Director of Production & Development Centre at Fujifilm Kyowa Kirin Biologics Co., Ltd. He was a senior researcher at Bio Process Research and Development Laboratories of Kyowa Hakko Kirin Co., Ltd. Dr. Tsumura is also involved in the academic world, presently serving as a Director of Japanese Association for Animal Cell Technology. He taught as a visiting professor at Tokyo University of Pharmacy and Life Sciences and Gunma University Graduate School, and as a visiting lecturer at Nagoya University Graduate School. He was the leader of BIO COP at ISPE Japan Affiliate. Dr. Tsumura graduated from Kyoto University with a B.S. & M.S. in Applied Microbiology. He holds a Ph.D. in Protein Chemistry from Niigata University.
Hiroshi Yamamoto, MBA
Corporate Officer, Business Head (Japan/Asia)
Initially in charge of domestic sales and Asian business at Eisai Co., Ltd., Mr. Yamamoto later moved to AbbVie Inc., where his business was related to the launch of the cranial nerve (Parkinson’s disease). At Santen Pharmaceutical Co., Ltd., he gained broad-ranging pan-Asian business expertise, handling the launch and management of business in the ASEAN region, as well as the management of the company’s business in China. While at Santen Pharmaceutical, he served as vice president of Santen China and president of Santen Asia, the company’s regional headquarters. Mr. Yamamoto holds a degree in chemical engineering from Doshisha University and an MBA from the National University of Singapore.
Michael P. McGrogan, Ph.D.,
Senior Production Development Fellow
Dr. McGrogan joined SanBio in 2003. Dr. McGrogan has over 25 years of biopharmaceutical R&D and production development experience. Prior to joining SanBio, Dr. McGrogan was Vice President of Research and Development at Layton BioScience (1996 to 2003). At Layton, Dr. McGrogan successfully managed the first cell therapy product to enter clinical trials for a CNS application, LBS-Neuron, from inception through a Phase II clinical trial. Prior to Layton, Dr. McGrogan held positions of increasing responsibility at several biotech companies including Berlex Biosciences, Invitron, and Cetus. Dr. McGrogan holds a Ph.D. in Molecular and Cellular Biology from Washington University School of Medicine, St. Louis, Missouri.
Corporate Officer, Management Administration
Previously, Mr. Kakutani was Executive Officer and General Manager of Finance Department of CareNet, Inc. (TSE, Mothers: 2150). Mr. Kakutani is a US Certified Public Accountant.